P Hirvikoski
Overview
Explore the profile of P Hirvikoski including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
24
Citations
442
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Jarviaho T, Halt K, Hirvikoski P, Moilanen J, Mottonen M, Niinimaki R
Clin Genet
. 2017 Aug;
93(2):392-395.
PMID: 28815563
Inherited bone marrow failure syndromes (IBMFS) are group of disorders that lead to inadequate production of blood cells. Mutations in genes involved in telomere maintenance, DNA repair, and the cell...
2.
Cord compression may rapidly influence the expression of placental angiogenic genes in pre-eclampsia
Jarvenpaa J, Vuoristo J, Ukkola O, Hirvikoski P, Savolainen E, Raudaskoski T, et al.
Placenta
. 2008 Apr;
29(5):436-8.
PMID: 18387671
Gene expression studies have demonstrated the altered expression level of placental angiogenesis related genes in severe pre-eclampsia (PE). In cord compression, the transportation of oxygen from the placenta to the...
3.
Vare P, Loikkanen I, Hirvikoski P, Vaarala M, Soini Y
Oncol Rep
. 2007 Dec;
19(1):25-31.
PMID: 18097572
The expression of claudins 1, 2, 3, 4, 5 and 7 was studied in prostate adenocarcinoma and compared to that of non-neoplastic epithelium and Gleason score of the tumors. Additionally,...
4.
Patrikainen L, Porvari K, Kurkela R, Hirvikoski P, Soini Y, Vihko P
Eur J Clin Invest
. 2007 Jan;
37(2):126-33.
PMID: 17217378
Background: The mechanisms behind prostate cancer progression are largely unknown, but macrophage inhibitory cytokine 1 (MIC-1) has been suggested to be involved in tumour dissemination in vivo due to its...
5.
Soini Y, Kallio J, Hirvikoski P, Helin H, Kellokumpu-Lehtinen P, Kang S, et al.
APMIS
. 2006 May;
114(5):329-37.
PMID: 16725008
Peroxiredoxins (Prxs) 1-6 were assessed in 138 renal cell carcinomas (RCC) using immunohistochemistry and selected samples by Western blotting analysis. Oxidative/nitrosative damage was evaluated using nitrotyrosine immunoreactivity. The expressions of...
6.
Soini Y, Kallio J, Hirvikoski P, Helin H, Kellokumpu-Lehtinen P, Tammela T, et al.
Histol Histopathol
. 2005 Dec;
21(2):157-65.
PMID: 16329040
The aim of the study was to estimate the significance of oxidative/nitrosative damage and expression of antioxidant enzymes in renal cell carcinomas (RCC). For this we investigated immunohistochemically six antioxidant...
7.
Membranous location of EGFR immunostaining is associated with good prognosis in renal cell carcinoma
Kallio J, Hirvikoski P, Helin H, Kellokumpu-Lehtinen P, Luukkaala T, Tammela T, et al.
Br J Cancer
. 2003 Oct;
89(7):1266-9.
PMID: 14520458
Epidermal growth factor receptor (EGFR) is a key factor in tumorigenesis. The association between EGFR expression and prognosis in renal cell carcinoma (RCC) is not clear. In our study of...
8.
Hirvikoski P, Virtaniemi J, Kumpulainen E, Johansson R, Kosma V
Eur J Cancer
. 2002 Aug;
38(13):1717-23.
PMID: 12175687
This study aimed to examine the clinical and biological differences in 198 patients with either T1-T2 local glottic or supraglottic squamous cell carcinomas. The patients with supraglottic cancer had a...
9.
10.
Virtaniemi J, Hirvikoski P, Kumpulainen E, Johansson R, Kulju T, Hujala K, et al.
Duodecim
. 2001 Sep;
114(13):1339-42.
PMID: 11552261
No abstract available.